Program
LM-2417
A development code.
In Sino Biopharmaceutical's pipeline, 41BBcondi/NaPi2b双抗
. Its studies are led by Sino Biopharmaceutical.
Furthest: phase 2, since Nov 7, 20241 company-led study, 1 open or runningNext primary completion: Dec 25, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 2since Nov 7, 2024 | Nov 7, 2024 | Dec 25, 2028phase 2 · NCT06682780 |
- Named in Sino Biopharmaceutical’s own pipeline as
LM-2417
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 7, 2024First study: phase 2 study in Advanced Solid TumorFirst studyNCT06682780 · 320 planned · China
Ahead
- Dec 25, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT06682780
TargetBeta
“41BBcondi/NaPi2b双抗”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06682780Advanced Solid Tumor · China | 2 | Recruiting | Dec 25, 2028 | 320 |
How it is read
Names in the registry
- “LM-2417”, 1 entry
Codes read as this program: LM2417.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.